MarketCap
Facebook
X
TelegramCellect Biotechnology Ltd. P/CF 2011-2026 | APOP
P/CF Jährlich Cellect Biotechnology Ltd.
| 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 |
|---|---|---|---|---|---|---|---|---|---|
| - | -23.7 | -59.9 | -261 | -91.3 | - | - | - | - | - |
Alle Zahlen in USD-Währung
Indikatorenreichweite aus Jahresberichten
| Höchstwert | Mindestwert | Durchschnitt |
|---|---|---|
| -23.7 | -261 | -109 |
P/CF anderer Aktien in der Pharmaeinzelhändler
| Name | P/CF | Preis | % 24h | Marktkapitalisierung | Land | |
|---|---|---|---|---|---|---|
 |
MorphoSys AG
MOR
|
-0.654 | - | 2.43 % | $ 254 M |  Germany |
 |
Anika Therapeutics
ANIK
|
-209 | $ 14.93 | 0.88 % | $ 219 M |  USA |
 |
Aptorum Group Limited
APM
|
-3.44 | $ 0.93 | 0.51 % | $ 5.07 M |  China |
 |
Aquestive Therapeutics
AQST
|
-8.91 | $ 4.14 | 0.36 % | $ 443 M | USA |
 |
Arcturus Therapeutics Holdings
ARCT
|
-2.92 | $ 8.39 | 4.5 % | $ 230 M |  Israel |
 |
Ardelyx
ARDX
|
-38.2 | $ 6.06 | 1.94 % | $ 1.46 B | USA |
 |
argenx SE
ARGX
|
-22.7 | $ 749.68 | 0.44 % | $ 25 B |  Niderland |
 |
Arcutis Biotherapeutics
ARQT
|
-612 | $ 23.93 | 1.27 % | $ 3.04 B | USA |
 |
Arvinas
ARVN
|
-3.17 | $ 11.36 | 4.7 % | $ 805 M | USA |
 |
I-Mab
IMAB
|
-0.266 | - | - | $ 866 M | China |
 |
Arrowhead Pharmaceuticals
ARWR
|
34.8 | $ 61.99 | 1.57 % | $ 8.29 B | USA |
 |
Alexion Pharmaceuticals, Inc.
ALXN
|
11.6 | - | - | $ 40.3 B | USA |
 |
Genfit SA
GNFT
|
1.68 K | - | 2.54 % | $ 160 B |  France |
 |
Assembly Biosciences
ASMB
|
-7.51 | $ 29.09 | 0.28 % | $ 326 M | USA |
 |
Biophytis SA
BPTS
|
-23.1 | - | -13.47 % | $ 169 M | France |
 |
Actinium Pharmaceuticals
ATNM
|
-1.26 | $ 1.13 | 15.26 % | $ 35.3 M | USA |
 |
Atossa Therapeutics
ATOS
|
-1.57 | $ 5.19 | -3.36 % | $ 44.7 M | USA |
 |
Atara Biotherapeutics
ATRA
|
-1.45 | $ 5.0 | 0.2 % | $ 62.7 M | USA |
 |
Midatech Pharma plc
MTP
|
-13.2 | - | -18.52 % | $ 27.3 M |  Britain |
 |
EyeGate Pharmaceuticals, Inc.
EYEG
|
-3.88 | - | -1.52 % | $ 24.7 M | USA |
 |
Aurinia Pharmaceuticals
AUPH
|
13.7 | $ 16.05 | 2.79 % | $ 2.16 B |  Canada |
 |
Autolus Therapeutics plc
AUTL
|
-1.14 | $ 1.41 | -0.35 % | $ 375 M | Britain |
 |
Acorda Therapeutics
ACOR
|
-1.2 | - | -24.86 % | $ 820 K | USA |
 |
Axon Enterprise
AXON
|
97.5 | $ 411.97 | -0.2 % | $ 31.2 B | USA |
 |
Aytu BioScience
AYTU
|
-8.14 | $ 2.65 | -1.12 % | $ 16.6 M | USA |
 |
Adverum Biotechnologies
ADVM
|
-0.826 | - | - | $ 86.2 M | USA |
 |
Advaxis
ADXS
|
-0.0633 | - | -9.65 % | $ 45.9 M | USA |
 |
Applied Molecular Transport
AMTI
|
-0.236 | - | - | $ 10.1 M | USA |
 |
Aeterna Zentaris
AEZS
|
-4.82 | - | 5.93 % | $ 314 M | Canada |
 |
AgeX Therapeutics
AGE
|
-0.0018 | - | -10.17 % | $ 12.2 K | USA |
 |
AIkido Pharma
AIKI
|
-1.17 | - | 1.93 % | $ 17.4 M | USA |
 |
Aeglea BioTherapeutics
AGLE
|
-4.6 | - | - | $ 1.01 B | USA |
 |
Applied Genetic Technologies Corporation
AGTC
|
-0.64 | - | - | $ 26.5 M | USA |
 |
Akero Therapeutics
AKRO
|
-14.1 | - | - | $ 3.67 B | USA |
 |
Akouos
AKUS
|
-2.7 | - | 0.23 % | $ 488 M | USA |
 |
Институт стволовых клеток человека
ISKJ
|
-89 | - | - | - |  Russia |
 |
BioCardia
BCDA
|
-1.08 | $ 1.18 | -1.67 % | $ 7.87 M | USA |
 |
BioCryst Pharmaceuticals
BCRX
|
-33 | $ 9.59 | 6.26 % | $ 1.98 B | USA |
 |
Allena Pharmaceuticals
ALNA
|
-2.48 | - | 3.16 % | $ 1.9 M | USA |
 |
Alpine Immune Sciences
ALPN
|
-6.14 | - | - | $ 2.17 B | USA |
 |
Aileron Therapeutics
ALRN
|
-1.71 | - | 10.36 % | $ 9.8 M | USA |
 |
Anavex Life Sciences Corp.
AVXL
|
-7.45 | $ 3.05 | 1.51 % | $ 260 M | USA |
 |
Biohaven Pharmaceutical Holding Company Ltd.
BHVN
|
-10.3 | $ 9.46 | -3.47 % | $ 612 M | USA |
 |
BioVie
BIVI
|
-0.128 | $ 1.46 | 2.81 % | $ 2.16 M | USA |
 |
BioLineRx Ltd.
BLRX
|
-57.4 | $ 2.32 | 4.98 % | $ 908 M | Israel |
 |
BioMarin Pharmaceutical
BMRN
|
14.1 | $ 56.04 | 0.96 % | $ 10.7 B | USA |
 |
BioNTech SE
BNTX
|
70.7 | $ 91.64 | 0.5 % | $ 27.2 B | Germany |
 |
Aravive
ARAV
|
-0.928 | - | -13.39 % | $ 1.45 M | USA |
 |
BioXcel Therapeutics
BTAI
|
-0.267 | $ 1.18 | -0.42 % | $ 14.4 M | USA |
 |
Burford Capital Limited
BUR
|
11.6 | $ 4.5 | 8.57 % | $ 683 M | Britain |